| |
Newsroom /
Health and Fitness
/
Healthcare
/
Stomach Cancer - Pipeline Assessment and Market Forecasts to 2017
Stomach Cancer - Pipeline Assessment and Market Forecasts to 2017
The Stomach Cancer Market is Forecast to Show Strong Growth Until 2017
Hyderabad,
AP,
India
(prbd.net)
26/10/2010
GlobalData’s analysis suggests that the global gastric cancer market was worth $750m in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.3% to $1,422m in 2017. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere’s generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in
demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the stomach cancer market. However, the new therapies are not expected go off-patent before 2017. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Stomach-Cancer-Pipeline-Assessment-and-Market-Forecast-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
GlobalData’s analysis suggests that all the chemotherapy regimens in the market have comparable efficacy profiles and offer a median overall survival of around 10-11 months. Most chemotherapies havem been off-patent for a long time while Taxotere and Xeloda are expected to go off-patent soon. In addition,the safety profiles of the three-drug chemotherapy regimens are not tolerable as the toxicities lead to discontinuation. The FDA approved combination DCF (Docetaxel, Cisplatin, 5-Fluorouracil) is the leading
treatment regimen for the treatment of advanced stomach cancer. In addition, there is currently no standard of treatment due to a lack of consensus over the most appropriate treatment regimen across the major geographies. Therefore, the competition among the marketed products is weak in the stomach cancer market.
The pipeline for gastric cancer market is strong with four promising therapies: cetuximab, lapatinib, IMC-1121B and everolimus. Cetuximab and lapatinib are in development for first-line treatment while IMC-1121B and everolimus are in development for the second-line treatment of advanced gastric cancer Everolimus is also in development for third-line treatment for gastric cancer. These drugs have shown promising results in their early development stages and are expected to increase demand in the market once approved.
GlobalData’s report, “Stomach Cancer – Pipeline Assessment and Market Forecasts to 2017”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline
products in the global stomach cancer segment.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Stomach-Cancer-Pipeline-Assessment-and-Market-Forecast-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|